Olmesartan Comparison to Losartan in Hypertensive Subjects

Phase 4 Completed 941 enrolled Daiichi Sankyo

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy and safety of the FDA approved blood pressure medication olmesartan medoxomil compared to the FDA approved medication losartan potassium.

Timeline

Start: 2009-08
Primary completion: 2010-01
Completion: 2010-01

Outcome

Met primary endpoint

registry LEAST_SQUARES_MEAN Combined Olmesartan: -9.7 (Standard Error 0.45) mmHg LEAST_SQUARES_MEAN Losartan: -7.1 (Standard Error 0.45) mmHg NCT00949884 ↗

registry analysis (superiority or other test); Combined Olmesartan vs Losartan; p <0.0001; Mean Difference (Final Values) -2.5 (95% CI -3.8 to -1.3); ANCOVA NCT00949884 ↗

Publications

Punzi HA, Lewin A, Li W, Chavanu KJ. Efficacy/safety of olmesartan medoxomil versus losartan potassium in naive versus previously treated subjects with hypertension. Adv Ther. 2012 Jun;29(6):524-37. doi: 10.1007/s12325-012-0029-5. Epub 2012 Jul 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Losartan	Other / unclassified	100 mg	Oral
Subject	Olmesartan medoxomil	Unknown	40 mg	Oral